Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $6
Benzinga Newsdesk 14 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Larry Biegelsen maintains RxSight (NASDAQ:RXST) with a Equal-Weight and lowers the price target from $9 to $6.
Wells Fargo analyst Larry Biegelsen maintains RxSight (NASDAQ:RXST) with a Equal-Weight and lowers the price target from $9 to $6.